NASDAQ:DERM - Dermira Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$9.92 -0.40 (-3.88 %)
(As of 12/14/2018 02:01 PM ET)
Previous Close$10.32
Today's Range$9.83 - $10.23
52-Week Range$6.98 - $31.42
Volume614,140 shs
Average Volume474,316 shs
Market Capitalization$455.33 million
P/E Ratio-2.26
Dividend YieldN/A
Beta0.94
Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DERM
Previous Symbol
CUSIPN/A
Phone650-421-7200

Debt

Debt-to-Equity Ratio5.21
Current Ratio5.29
Quick Ratio5.25

Price-To-Earnings

Trailing P/E Ratio-2.26
Forward P/E Ratio-1.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.54 million
Price / Sales92.03
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.59 per share
Price / Book2.76

Profitability

EPS (Most Recent Fiscal Year)($4.39)
Net Income$-303,260,000.00
Net Margins-496.49%
Return on Equity-184.43%
Return on Assets-41.67%

Miscellaneous

Employees162
Outstanding Shares42,120,000
Market Cap$455.33 million
OptionableOptionable

Dermira (NASDAQ:DERM) Frequently Asked Questions

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.63) by $0.05. The biopharmaceutical company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.80 million. Dermira had a negative net margin of 496.49% and a negative return on equity of 184.43%. View Dermira's Earnings History.

When is Dermira's next earnings date?

Dermira is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Dermira.

What price target have analysts set for DERM?

6 brokers have issued 1 year price targets for Dermira's shares. Their predictions range from $10.00 to $48.00. On average, they expect Dermira's share price to reach $23.1667 in the next twelve months. This suggests a possible upside of 135.0% from the stock's current price. View Analyst Price Targets for Dermira.

What is the consensus analysts' recommendation for Dermira?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.

What are Wall Street analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:
  • 1. Cantor Fitzgerald analysts commented, ". Post DERM’s solid quarter of execution, we reiterate our OW rating and 12-month price target of $20 for DERM shares. We think there is not enough value being attributed to DERM’s two key assets: 1) Qbrexza (glycopyrronium) for hyperhidrosis (excessive sweating) and 2) lebrikizumab for atopic dermatitis. The launch of Qbrexza and pipeline advancements for lebrikizumab should drive upward earnings revisions to levels not yet reflected in sell-side consensus expectations and DERM’s stock higher." (11/7/2018)
  • 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (10/10/2018)
  • 3. Mizuho analysts commented, "We previously modeled $302.5M for and our estimate remains relatively unchanged. We reiterate our Neutral rating and $10 PT." (10/2/2018)

Has Dermira been receiving favorable news coverage?

Press coverage about DERM stock has trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dermira earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the stock's share price in the next few days.

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:
  • Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)
  • Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)
  • Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 50)
  • Mr. Luis C. Peña, Chief Devel. Officer (Age 55)
  • Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 41)

Who are Dermira's major shareholders?

Dermira's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc (3.99%), Vanguard Group Inc. (3.99%), Dimensional Fund Advisors LP (2.19%), Sofinnova Ventures Inc (1.18%), C WorldWide Group Holding A S (0.97%) and Fosun International Ltd (0.84%). Company insiders that own Dermira stock include Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Matthew K Fust, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.

Which institutional investors are selling Dermira stock?

DERM stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, C WorldWide Group Holding A S, Vanguard Group Inc., Vanguard Group Inc, Trexquant Investment LP and TIAA CREF Investment Management LLC. Company insiders that have sold Dermira company stock in the last year include Christopher M Griffith, David E Cohen, Eugene A Bauer and Matthew K Fust. View Insider Buying and Selling for Dermira.

Which institutional investors are buying Dermira stock?

DERM stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Dimensional Fund Advisors LP, Point72 Asset Management L.P., Renaissance Technologies LLC, Sofinnova Ventures Inc, Panagora Asset Management Inc., Bailard Inc. and Opaleye Management Inc.. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira.

How do I buy shares of Dermira?

Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $9.86.

How big of a company is Dermira?

Dermira has a market capitalization of $455.33 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe.

What is Dermira's official website?

The official website for Dermira is http://www.dermira.com.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]


MarketBeat Community Rating for Dermira (NASDAQ DERM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel